Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells
- 31 December 2003
- journal article
- research article
- Published by Elsevier BV in Immunobiology
- Vol. 207 (2), 85-93
- https://doi.org/10.1078/0171-2985-00219
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptorImmunology, 1999
- Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cellsBone Marrow Transplantation, 1998
- Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgerySurgical Oncology, 1994
- Chemotherapy‐induced differential changes in lymphocyte subsets and natural‐killer‐cell function in patients with advanced breast cancerInternational Journal of Cancer, 1993
- Distinct Phenotypic and Functional Characteristics of Human Natural Killer Cells Obtained by Rapid Interleukin 2-Induced Adherence to PlasticCellular Immunology, 1993
- CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.The Journal of Experimental Medicine, 1991
- Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.The Journal of Experimental Medicine, 1991
- Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.The Journal of Experimental Medicine, 1990
- Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.The Journal of Experimental Medicine, 1990
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985